By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalex, Inc. 



Albuquerque  New Mexico  87190  U.S.A.
Phone: 505-260-1726 Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Protalex, Inc. (PRTX) Announces Listing On OTCQB Exchange 7/21/2015 11:01:48 AM
Protalex, Inc. (PRTX) Receives Orphan Drug Designation From FDA For PRTX-100 To Treat Immune Thrombocytopenia 6/16/2015 9:48:39 AM
Protalex, Inc. (PRTX) Announces Findings From Final Cohort Of U.S. Phase Ib Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/16/2015 10:59:13 AM
Protalex, Inc. (PRTX) Announces FDA Acceptance Of Investigational New Drug Application For PRTX-100 To Treat Immune Thrombocytopenia 3/31/2015 11:33:04 AM
Protalex, Inc. (PRTX) Initiates Enrollment Of Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 3/12/2015 8:11:52 AM
Protalex, Inc. (PRTX) Announces Data From Phase 1b Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis Treated For Longer Duration Shows Safety And Reduction In Disease Activity 11/17/2014 12:47:23 PM
Protalex, Inc. (PRTX) To Present At Rodman & Renshaw Annual Global Investment Conference 9/5/2014 12:15:10 PM
Protalex, Inc. (PRTX) Announces Acceptance Of Abstract Highlighting Findings From U.S. Phase 1(B) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients At The 2014 American College of Rheumatology Annual Meeting 9/3/2014 9:01:22 AM
Protalex, Inc. (PRTX) Announces Data from U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients Presented At The 2014 EULAR Annual European Congress of Rheumatology 6/13/2014 7:56:52 AM
Protalex, Inc. (PRTX) Announces Preliminary Unblinded Findings From Cohorts 1-4 Of U.S. Phase 1b Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 6/3/2014 9:34:36 AM
1234567
//-->